(Q44985072)

English

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 December 2017

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study (English)

1 reference

Europe PubMed Central

8 December 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Wolfram Samlowski

8

1 reference

Europe PubMed Central

8 December 2017

David S. Alberts

10

object named as

David S Alberts

1 reference

Europe PubMed Central

8 December 2017

author name string

Patrick J Stiff

1

1 reference

Europe PubMed Central

8 December 2017

Elizabeth J Shpall

2

1 reference

Europe PubMed Central

8 December 2017

P Y Liu

3

1 reference

Europe PubMed Central

8 December 2017

Sharon P Wilczynski

4

1 reference

Europe PubMed Central

8 December 2017

Natalie S Callander

5

1 reference

Europe PubMed Central

8 December 2017

Sidney A Scudder

6

1 reference

Europe PubMed Central

8 December 2017

Abdul-Rahman Jazieh

7

1 reference

Europe PubMed Central

8 December 2017

Jason McCoy

9

1 reference

Europe PubMed Central

8 December 2017

Southwest Oncology Group Study

11

1 reference

Europe PubMed Central

8 December 2017

language of work or name

0 references

publication date

1 July 2004

1 reference

Europe PubMed Central

8 December 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

8 December 2017

94

1 reference

Europe PubMed Central

8 December 2017

98-106

1 reference

Europe PubMed Central

8 December 2017

1

1 reference

Europe PubMed Central

8 December 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Clinical pharmacology of intraperitoneal cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Emerging treatments for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Optimal sequencing in the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Intraperitoneal treatment and dose-intense therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.02.032

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.02.032

1 reference

Europe PubMed Central

8 December 2017

1 reference

Europe PubMed Central

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44985072&oldid=2076555505"